Status:
ACTIVE_NOT_RECRUITING
Adherence and Clinical Correlates in Persons With HIV on TAF
Lead Sponsor:
University of Colorado, Denver
Conditions:
Hiv
Eligibility:
All Genders
18-89 years
Brief Summary
This is an observational, 48-week, prospective study of PWH treated with TAF in which the investigators will compare TFV-DP concentrations in DBS in virologically suppressed vs. non-suppressed individ...
Detailed Description
Antiretroviral (ARV) drug exposure is directly linked to individual host factors, including age, weight, diet, and genetics. However, the main factor influencing long-term drug exposure is drug adhere...
Eligibility Criteria
Inclusion
- Females or males with HIV (≥18 years), able to give informed consent and comply with study procedures who are having a blood draw as part of their regular clinical care.
- Being prescribed TAF-based ART \>= 3 months.
Exclusion
- 1\. For females, active pregnancy or intent to become pregnant.
Key Trial Info
Start Date :
April 25 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2025
Estimated Enrollment :
384 Patients enrolled
Trial Details
Trial ID
NCT05335590
Start Date
April 25 2022
End Date
October 1 2025
Last Update
June 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Health
Aurora, Colorado, United States, 80045